Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells 58,333 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 58,333 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $13.90, for a total value of $810,828.70. Following the completion of the transaction, the insider owned 767,486 shares of the company’s stock, valued at $10,668,055.40. The trade was a 7.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

David Kirn also recently made the following trade(s):

• On Monday, August 3rd, David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.05, for a total value of $124,770.75.
• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.03, for a total value of $189,171.75.
• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.87, for a total value of $548,364.96.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62.

4D Molecular Therapeutics Trading Up 1.0%

Shares of FDMT stock traded up $0.13 during mid-day trading on Wednesday, reaching $13.76. 819,575 shares of the stock traded hands, compared to its average volume of 825,918. The stock’s fifty day simple moving average is $12.68 and its two-hundred day simple moving average is $10.75. 4D Molecular Therapeutics, Inc. has a 1-year low of $6.47 and a 1-year high of $16.93. The company has a market cap of $760.10 million, a price-to-earnings ratio of -5.23 and a beta of 2.74. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The firm had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. On average, research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in FDMT. Persistent Asset Partners Ltd acquired a new position in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $1,936,000. Deutsche Bank AG bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $9,456,000. Dimensional Fund Advisors LP increased its position in shares of 4D Molecular Therapeutics by 77.3% during the first quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock worth $4,863,000 after buying an additional 227,982 shares during the period. Exome Asset Management LLC acquired a new stake in shares of 4D Molecular Therapeutics during the first quarter worth $1,216,000. Finally, Perigon Wealth Management LLC bought a new position in 4D Molecular Therapeutics during the second quarter worth $1,944,000. Institutional investors own 99.27% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. Cantor Fitzgerald raised 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 target price for the company in a research report on Monday. The Goldman Sachs Group reaffirmed a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. Finally, B. Riley Financial reaffirmed a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $28.56.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.